NeoGenomics
About: NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Employees: 2,200
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
789% more call options, than puts
Call options by funds: $15.6M | Put options by funds: $1.76M
11% more capital invested
Capital invested by funds: $1.82B [Q3] → $2.02B (+$202M) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
0.82% less ownership
Funds ownership: 96.34% [Q3] → 95.52% (-0.82%) [Q4]
6% less funds holding
Funds holding: 267 [Q3] → 250 (-17) [Q4]
18% less repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 95
35% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 34
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Goldman Sachs Matthew Sykes 41% 1-year accuracy 14 / 34 met price target | 57%upside $15 | Buy Maintained | 17 Apr 2025 |
Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target | 88%upside $18 | Overweight Maintained | 26 Feb 2025 |
B of A Securities Derik De Bruin 35% 1-year accuracy 7 / 20 met price target | 67%upside $16 | Neutral Maintained | 19 Feb 2025 |
Needham Mike Matson 22% 1-year accuracy 27 / 121 met price target | 88%upside $18 | Buy Maintained | 19 Feb 2025 |
Financial journalist opinion
Based on 3 articles about NEO published over the past 30 days









